Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia

Ko,Chung-Po; Yu,Yung-Luen; Hsiao,Pei-Ching; Yang,Shun-Fa; Yeh,Chao-Bin

doi:10.3892/mmr.2014.1933

Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia

Authors:
- Chung-Po Ko
- Yung-Luen Yu
- Pei-Ching Hsiao
- Shun-Fa Yang
- Chao-Bin Yeh
View Affiliations

Affiliations: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C., Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University, Taichung 402, Taiwan, R.O.C., School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
Published online on: February 6, 2014 https://doi.org/10.3892/mmr.2014.1933
Pages: 1400-1404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to examine the plasma level changes of soluble Axl (sAxl) prior to and following treatment with antibiotics in hospitalized adult patients with community-acquired pneumonia (CAP), and to investigate the correlating clinical and laboratory manifestations of CAP with plasma sAxl levels. Blood samples were obtained from 61 adult CAP patients (prior to and following treatment with antibiotics) and 60 healthy controls in order to measure the plasma concentrations of sAxl using the enzyme-linked immunosorbent assay. The plasma-soluble Axl concentration level was markedly elevated in patients with CAP prior to treatment, compared with the controls, and decreased markedly following treatment. The levels of white blood cells, neutrophils, and C-reactive protein decreased markedly following treatment with antibiotics and did not correlate with the concentration level of sAxl. However, the plasma concentration of sAxl correlated with the severity of CAP with the pneumonia severity index score (r=0.350, P=0.006, n=61), the CURB-65 score (r=0.281, P=0.028, n=61) and the acute physiology and chronic health evaluation II score (r=0.313, P=0.014, n=61). In conclusion, plasma sAxl may be involved in the clinical assessment of the severity of CAP, which may guide the development of treatment strategies and predict the clinical outcome.

View Figures

View References

1	Kumar V, Abbas AK, Fausto N, et al: Pathologic Basis of Disease. 8th ed. Elsevier Saunders; Philadelphia, PA: pp. 710–711. 2009
2	Chiang TY, Shyu LY, Tsao TC, et al: Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin Chem Lab Med. 50:449–454. 2011.PubMed/NCBI
3	Lee YT, Chen SC, Shyu LY, et al: Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta. 413:630–635. 2012. View Article : Google Scholar : PubMed/NCBI
4	Houck PM, Bratzler DW, Nsa W, Ma A and Bartlett JG: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 164:637–644. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ekman C, Gottsäter A, Lindblad B and Dahlbäck B: Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia. Clin Biochem. 43:873–876. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ekman C, Linder A, Akesson P and Dahlbäck B: Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care. 14:R1582010. View Article : Google Scholar
7	Hafizi S and Dahlbäck B: Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273:5231–5244. 2006.PubMed/NCBI
8	Gheita TA, Bassyouni IH and Bassyouni RH: Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with Systemic lupus erythematosus and Behçets disease. J Clin Immunol. 32:1279–1286. 2012.
9	Mandell LA, Wunderink RG, Anzueto A, et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management ofcommunity-acquired pneumonia in adults. Clin Infect Dis. 44:S27–S72. 2007. View Article : Google Scholar
10	Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:243–250. 1997. View Article : Google Scholar : PubMed/NCBI
11	Knaus WA, Draper EA, Wagner DP, et al: APACHE II: a severity of disease classification system. Crit Care Med. 13:818–829. 1985. View Article : Google Scholar : PubMed/NCBI
12	Lim WS, van der Eerden MM, Laing R, et al: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 58:377–382. 2003. View Article : Google Scholar : PubMed/NCBI
13	Melaragno MG, Wuthrich DA, Poppa V, et al: Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res. 83:697–704. 1998. View Article : Google Scholar : PubMed/NCBI
14	Ekman C, Site DF, Gottsäter A, Lindblad B and Dahlbäck B: Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 43:110–114. 2010. View Article : Google Scholar : PubMed/NCBI
15	Robinson DR, Wu YM and Lin SF: The protein tyrosine kinase family of the human genome. Oncogene. 19:5548–5557. 2000. View Article : Google Scholar : PubMed/NCBI
16	Linger RM, Keating AK, Earp HS and Graham DK: TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
17	Manfioletti G, Brancolini C, Avanzi G and Schneider C: The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 13:4976–4985. 1993.
18	O’Bryan JP, Frye RA, Cogswell PC, et al: Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 11:5016–5031. 1991.PubMed/NCBI
19	Vajkoczy P, Knyazev P, Kunkel A, et al: Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA. 103:5799–5804. 2006. View Article : Google Scholar : PubMed/NCBI
20	Sawabu T, Seno H, Kawashima T, et al: Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 46:155–164. 2007. View Article : Google Scholar : PubMed/NCBI
21	Lee IJ, Hilliard B, Swami A, et al: Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrol Dial Transplant. 27:4166–4172. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ekman C, Jönsen A, Sturfelt G, Bengtsson AA and Dahlbäck B: Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 50:1064–1069. 2011. View Article : Google Scholar : PubMed/NCBI